PL2229356T3 - 1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic - Google Patents
1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnicInfo
- Publication number
- PL2229356T3 PL2229356T3 PL08857355T PL08857355T PL2229356T3 PL 2229356 T3 PL2229356 T3 PL 2229356T3 PL 08857355 T PL08857355 T PL 08857355T PL 08857355 T PL08857355 T PL 08857355T PL 2229356 T3 PL2229356 T3 PL 2229356T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- pidemia
- hyperli
- benzylamino
- arteriosclerosis
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- -1 1,2-disubstituted-4-benzylamino-pyrrolidine Chemical class 0.000 title 1
- 206010003210 Arteriosclerosis Diseases 0.000 title 1
- 208000031226 Hyperlipidaemia Diseases 0.000 title 1
- 208000011775 arteriosclerosis disease Diseases 0.000 title 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title 1
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 abstract 3
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 abstract 3
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99189107P | 2007-12-03 | 2007-12-03 | |
| EP08857355A EP2229356B1 (en) | 2007-12-03 | 2008-12-01 | 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis |
| PCT/EP2008/066537 WO2009071509A1 (en) | 2007-12-03 | 2008-12-01 | 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2229356T3 true PL2229356T3 (pl) | 2012-03-30 |
Family
ID=40347796
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08857355T PL2229356T3 (pl) | 2007-12-03 | 2008-12-01 | 1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic |
| PL11184000T PL2404901T3 (pl) | 2007-12-03 | 2008-12-01 | 1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11184000T PL2404901T3 (pl) | 2007-12-03 | 2008-12-01 | 1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8759365B2 (pl) |
| EP (2) | EP2229356B1 (pl) |
| JP (1) | JP5421282B2 (pl) |
| KR (1) | KR20100093103A (pl) |
| CN (1) | CN101878199B (pl) |
| AT (1) | ATE528289T1 (pl) |
| AU (1) | AU2008333272B2 (pl) |
| BR (1) | BRPI0820000A2 (pl) |
| CA (1) | CA2707651A1 (pl) |
| EA (1) | EA017939B1 (pl) |
| ES (2) | ES2375527T3 (pl) |
| MX (1) | MX2010006063A (pl) |
| PL (2) | PL2229356T3 (pl) |
| PT (2) | PT2404901E (pl) |
| WO (1) | WO2009071509A1 (pl) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090286790A1 (en) * | 2006-07-20 | 2009-11-19 | Hidetomo Imase | Organic compounds |
| AR069165A1 (es) | 2007-11-05 | 2010-01-06 | Novartis Ag | Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia |
| CA2804924C (en) | 2010-07-09 | 2016-06-28 | Daiichi Sankyo Company, Limited | Substituted pyridine compound |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| BR112013008527A2 (pt) | 2010-12-17 | 2016-07-12 | Nerviano Medical Sciences Srl | derivados de pirazolo-quinazolina substituídos como inibidores de cinase |
| EP2668507B1 (en) | 2011-01-26 | 2017-08-23 | INSERM - Institut National de la Santé et de la Recherche Médicale | Method for assessing a subject's risk of having a cardiovascular disease. |
| PL2729142T3 (pl) * | 2011-07-08 | 2018-10-31 | Novartis Ag | Sposób leczenia miażdżycy tętnic u osobników z wysokim poziomem triglicerydów |
| WO2013103150A1 (ja) | 2012-01-06 | 2013-07-11 | 第一三共株式会社 | 置換ピリジン化合物の酸付加塩 |
| US20130245259A1 (en) * | 2012-03-16 | 2013-09-19 | Natco Pharma Limited | Process for the preparation of bosentan monohydrate |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| NZ710574A (en) | 2013-02-14 | 2017-11-24 | Novartis Ag | Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors |
| US9266925B2 (en) | 2013-07-25 | 2016-02-23 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure |
| BR112016001376A2 (pt) | 2013-07-25 | 2017-10-24 | Novartis Ag | bioconjugados de polipeptídeos de apelin sintéticos |
| CA2972871A1 (en) | 2015-01-23 | 2016-07-28 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| WO2022216848A1 (en) * | 2021-04-06 | 2022-10-13 | Hemoshear Therapeutics, Inc. | Methods of treating methylmalonic acidemia and propionic acidemia |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
| US4889861A (en) | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
| RU2086544C1 (ru) | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| US5508272A (en) | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
| MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| TW313568B (pl) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
| EA008060B1 (ru) | 1998-09-04 | 2007-02-27 | Милленниум Фармасьютикалз, Инк. | Антагонисты хемокинного рецептора и способы их применения |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| US6140342A (en) | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
| PT1115695E (pt) | 1998-09-25 | 2005-10-31 | Monsanto Co | (n+1) -alcanois 1-aminossubstituidos (r) -quirais halogenados uteis para inibir a actividade da proteina de transferencia de ester de colesterilo |
| AUPP818099A0 (en) | 1999-01-14 | 1999-02-11 | Fujisawa Pharmaceutical Co., Ltd. | New n-containing heterocyclic compounds |
| US6451823B1 (en) * | 1999-09-23 | 2002-09-17 | G.D. Searle & Co. | Use of substituted N-phenoxy-N-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity |
| AU7549501A (en) | 2000-06-16 | 2002-01-02 | Biogen Inc | Angiogenesis-modulating compositions and uses |
| GB0021885D0 (en) | 2000-09-06 | 2000-10-18 | Fujisawa Pharmaceutical Co | New use |
| WO2003011837A1 (en) | 2001-08-01 | 2003-02-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| EP1448566B3 (en) * | 2001-11-21 | 2009-04-08 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use thereof |
| WO2003047569A1 (en) | 2001-12-03 | 2003-06-12 | Gpc Biotech, Inc. | Compositions and methods for inhibiting prenyltransferases |
| EP2277551B1 (en) | 2002-09-06 | 2013-05-08 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto |
| TW200408393A (en) | 2002-10-03 | 2004-06-01 | Ono Pharmaceutical Co | Antagonist of lysophosphatidine acid receptor |
| WO2004050654A1 (ja) * | 2002-11-29 | 2004-06-17 | Shionogi & Co., Ltd. | ピロリジン化合物の合成とその塩 |
| US20070010529A1 (en) * | 2003-05-19 | 2007-01-11 | Kanji Takahashi | Nitrogenous heterocyclic compounds and medical use thereof |
| EP1670765A2 (en) | 2003-09-30 | 2006-06-21 | Pfizer Products Inc. | Cetp inhibitors and metabolites thereof |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| EA200601785A1 (ru) | 2004-03-26 | 2007-02-27 | Эли Лилли Энд Компани | Соединения и способы лечения дислипидемии |
| UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| MY139887A (en) * | 2004-04-02 | 2009-11-30 | Mitsubishi Tanabe Pharma Corp | Tetrahydronaphthyridine derivatives and a process for preparing the same. |
| US7714021B2 (en) | 2004-06-15 | 2010-05-11 | Merck & Co., Inc. | Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease |
| US20060063803A1 (en) * | 2004-09-23 | 2006-03-23 | Pfizer Inc | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds |
| WO2006069162A1 (en) * | 2004-12-20 | 2006-06-29 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds and their pharmaceutical compositions |
| US20060270675A1 (en) * | 2005-03-10 | 2006-11-30 | Groneberg Robert D | Inhibitors of cholesterol ester transfer protein |
| WO2006098394A1 (ja) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | 脂質吸収抑制方法および脂質吸収抑制剤 |
| MY150958A (en) | 2005-06-16 | 2014-03-31 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
| UY30118A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compueto amina trisustituido |
| WO2007107843A1 (en) | 2006-03-22 | 2007-09-27 | Pfizer Products Inc. | Methods of treatment with cetp inhibitors |
| TW200808731A (en) * | 2006-03-30 | 2008-02-16 | Tanabe Seiyaku Co | A process for preparing tetrahydroquinoline derivatives |
| US20090286790A1 (en) * | 2006-07-20 | 2009-11-19 | Hidetomo Imase | Organic compounds |
| JP4846769B2 (ja) | 2007-07-30 | 2011-12-28 | 田辺三菱製薬株式会社 | 医薬組成物 |
| JP4834699B2 (ja) | 2007-07-30 | 2011-12-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
| AR069165A1 (es) * | 2007-11-05 | 2010-01-06 | Novartis Ag | Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia |
| JP2011506303A (ja) | 2007-12-07 | 2011-03-03 | ノバルティス アーゲー | ピラゾール誘導体およびサイクリン依存性キナーゼの阻害剤としてのその使用 |
-
2008
- 2008-12-01 PT PT111840005T patent/PT2404901E/pt unknown
- 2008-12-01 EP EP08857355A patent/EP2229356B1/en not_active Not-in-force
- 2008-12-01 BR BRPI0820000-9A patent/BRPI0820000A2/pt not_active IP Right Cessation
- 2008-12-01 PL PL08857355T patent/PL2229356T3/pl unknown
- 2008-12-01 US US12/745,105 patent/US8759365B2/en not_active Expired - Fee Related
- 2008-12-01 JP JP2010536418A patent/JP5421282B2/ja not_active Expired - Fee Related
- 2008-12-01 AT AT08857355T patent/ATE528289T1/de active
- 2008-12-01 KR KR1020107014702A patent/KR20100093103A/ko not_active Withdrawn
- 2008-12-01 AU AU2008333272A patent/AU2008333272B2/en not_active Ceased
- 2008-12-01 MX MX2010006063A patent/MX2010006063A/es active IP Right Grant
- 2008-12-01 ES ES08857355T patent/ES2375527T3/es active Active
- 2008-12-01 CN CN2008801170746A patent/CN101878199B/zh not_active Expired - Fee Related
- 2008-12-01 EA EA201000884A patent/EA017939B1/ru not_active IP Right Cessation
- 2008-12-01 PL PL11184000T patent/PL2404901T3/pl unknown
- 2008-12-01 WO PCT/EP2008/066537 patent/WO2009071509A1/en not_active Ceased
- 2008-12-01 PT PT08857355T patent/PT2229356E/pt unknown
- 2008-12-01 ES ES11184000T patent/ES2425776T3/es active Active
- 2008-12-01 EP EP11184000.5A patent/EP2404901B1/en not_active Not-in-force
- 2008-12-01 CA CA2707651A patent/CA2707651A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE528289T1 (de) | 2011-10-15 |
| EP2229356B1 (en) | 2011-10-12 |
| WO2009071509A1 (en) | 2009-06-11 |
| EA017939B1 (ru) | 2013-04-30 |
| ES2375527T3 (es) | 2012-03-01 |
| PT2229356E (pt) | 2012-01-20 |
| CA2707651A1 (en) | 2009-06-11 |
| BRPI0820000A2 (pt) | 2015-05-19 |
| ES2425776T3 (es) | 2013-10-17 |
| KR20100093103A (ko) | 2010-08-24 |
| US20100311750A1 (en) | 2010-12-09 |
| CN101878199A (zh) | 2010-11-03 |
| JP2011505405A (ja) | 2011-02-24 |
| JP5421282B2 (ja) | 2014-02-19 |
| AU2008333272A1 (en) | 2009-06-11 |
| PL2404901T3 (pl) | 2013-10-31 |
| EP2229356A1 (en) | 2010-09-22 |
| EA201000884A1 (ru) | 2011-02-28 |
| EP2404901A1 (en) | 2012-01-11 |
| US8759365B2 (en) | 2014-06-24 |
| MX2010006063A (es) | 2010-07-01 |
| PT2404901E (pt) | 2013-08-29 |
| EP2404901B1 (en) | 2013-05-22 |
| AU2008333272B2 (en) | 2012-03-29 |
| CN101878199B (zh) | 2013-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2404901E (pt) | Derivados de 4-benzilamino-pirrolidina 1,2-dissubstituídos como inibidores de cetp úteis para o tratamento de doenças tais como a hiperlipidemia ou a arteriosclerose | |
| TN2009000012A1 (en) | Amino-piperidine derivatives as cetp inhibitors | |
| JO2732B1 (en) | Organic compounds | |
| MX2009006630A (es) | Derivados de 4-imidazolil-1,2,3,4-tetrahidro-quinola y su uso como inhibidores de aldosterona / 11-beta-hidroxilasa. | |
| GEP20115306B (pl) | ||
| WO2007026920A3 (en) | Amide derivatives as rock inhibitors | |
| TNSN08444A1 (en) | Bicyclic derivatives as cetp inhibitors | |
| ATE537175T1 (de) | Neue piperazino-dihydrothienopyrimidin-derivate | |
| MX2012002752A (es) | Compuestos de heteroarilo como inhibidores de cinasa. | |
| EA201070864A1 (ru) | Новые гетероциклические соединения | |
| IN2012DN01273A (pl) | ||
| MX2010008226A (es) | Derivados de difluorobifenilamida para el tratamiento de hipertension ocular. | |
| MX2010002042A (es) | Derivados de 1,3-dihidroisoindol. | |
| CY1111327T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος | |
| MX2008010884A (es) | Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1. | |
| DE602007001463D1 (de) | Pyrimidin-, chinazolin-, pteridin- und triazinderivate | |
| ATE517873T1 (de) | 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten | |
| MY158069A (en) | Tricyclic compound and pharmaceutical use thereof | |
| DE602007011434D1 (de) | 1h-indol-5-ylpiperazin-1-ylmethanonderivate | |
| MX2009004982A (es) | Derivados heterociclicos como inhibidores cetp. | |
| MX2009005249A (es) | Compuestos organicos. | |
| EA201200866A1 (ru) | Ингибиторы цистеиновых протеаз | |
| EA200700360A1 (ru) | Новые производные амида гетероциклической карбоновой кислоты | |
| ATE438617T1 (de) | Substituierte cyclohexyl-1,4-diamin-derivate | |
| ATE466007T1 (de) | 5-substituierte indol-2-carbonsäureamidderivate |